TransMedics Group, Inc. (TMDX): Valuation
TTM figures as of June 30, 2026
TransMedics Group, Inc. trades at 18.8 times trailing earnings and a 2.77% free-cash-flow yield. On P/E that is higher than 11% of its own month-end history back to 2019. The Healthcare median P/E is 22.9.
Earnings yield 5.32%. ROIC 9.6%. Piotroski F-score 4 of 9. Net debt $330.8M.
88 month-end valuation observations are on file, starting May 2019.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is TMDX cheap versus its own history?
TransMedics Group, Inc. trades at 18.8 times trailing earnings and a 2.77% free-cash-flow yield. On P/E that is higher than 11% of its own month-end history back to 2019. The Healthcare median P/E is 22.9.
What is TMDX's free-cash-flow yield?
TransMedics Group, Inc. currently yields 2.77% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.